PANOVA-4: Pilot, Single arm Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Latest Information Update: 05 May 2026
At a glance
- Drugs Atezolizumab (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic ductal carcinoma
- Focus Therapeutic Use
- Acronyms PANOVA-4
- Sponsors Bio-America
Most Recent Events
- 30 Apr 2026 Status changed from active, no longer recruiting to completed.
- 26 Feb 2026 According to a Novocure Limited media release, topline data from this study is expected in Q1 2026.
- 24 Apr 2025 According to a Novocure Limited media release, data from this study is expected in 1H 2026.